Therapeutic plasma exchange, consisting of removing blood plasma and exchanging it with donated blood products, has been proposed for treating Alzheimer's disease (AD) to remove senescent or toxic factors. In preclinical studies, administration of plasma from young healthy mice to AD transgenic mice improved cognitive deficits without affecting brain amyloid plaques. Initial encouraging results have been collected in a double-blind, placebo-controlled study in nine AD patients receiving young plasma.
D-aspartate (NMDA)-antagonist memantine may temporarily improve symptoms. New drug development in AD is very slow and suffers a high attrition rate. Molecules showing promise in animal studies have not confirmed that promise in the clinic.
PATHOPHYSIOLOGY AND ANTI-Ab THERAPEUTIC APPROACHES TO ALZHEIMER'S DISEASE
The AD brain is histologically characterized by the presence of intracellular neurofibrillary tangles and extracellular plaques. The plaques are composed of A , a 40-to 42-amino acid peptide mediating physiological neuronal homeostasis. Neurofibrillary tangles are aggregates of the hyperphosphorylated form of tau, a protein involved in the stabilization of axonal microtubules. Other histopathological markers of the AD brain are dysfunctional microglia, reactive astrocytes, and dystrophic neurites. The A cascade hypothesis of AD assumes that the brain accumulation of A represents the initial event of the pathological process and starts 15 to 20 years before clinical symptoms become apparent. Point mutations of the amyloid precursor protein (APP) and the enzymes involved in its processing (PSEN1 and PSEN2) alter the production of A and cause the autosomal dominant familial forms of AD. A specific mutation of APP (A673T) was found to protect against AD onset and cognitive decline in cognitively healthy elderly individuals. The mutant amino acid is adjacent to the cleavage site of the -site amyloid precursor protein cleaving enzyme-1 (BACE1) and results in about a 40% reduction in A production in vitro. In late-onset sporadic AD, accumulation of brain A has been attributed to faulty clearance or increased BACE1 activity. A accumulation has also been linked to the apolipoprotein E 4 (APOE* 4) allele, the most important genetic risk factor associated with sporadic AD. These observations represent the foundation of the amyloid hypothesis of AD and during the last 20 years intensive efforts have been made to identify compounds which antagonize the accumulation of A in the AD brain. This objective was mainly pursued through two approaches. One was to reduce A production by inhibiting the two key enzymes (BACE1 and -secretase) which cleave APP to generate A . The other approach was to enhance A clearance from the brain with active or passive immunotherapy. Unfortunately, neither of these had therapeutic effects in patients with mild-to-moderate AD. 1 From these failures the AD scientific community concluded that the mild-to-moderate stage of AD is too late for the anti-A drugs to reverse or halt the progression of the disease. In addition, because about 25% of mildly affected patients enrolled in clinical trials did not have evidence of A brain deposition, new AD diagnostic criteria were proposed to define dementia due to AD based on biomarker evidence of brain amyloidosis. This enabled the definition of preclinical stages of AD to allow early pharmacological intervention. 2 Nevertheless, two large Phase 3 studies in prodromal AD patients (CREAD 1 and 2) with crenezumab, a monoclonal antibody directed against oligomeric A 3 and one large Phase 3 study (APECS) with verubecestat, 4 a potent BACE1 inhibitor, were prematurely terminated because they failed to show clinical efficacy. The results of the APECS study were fully published and were surprising because, although the levels of A deposition in the brain and A in the cerebrospinal fluid decreased, cognitive function and the structural brain imaging findings worsened with verubecestat compared to placebo. Furthermore, a Phase 3 trial with atabecestat, another potent BACE1 inhibitor, in cognitively normal subjects with biomarker evidence of brain A deposition, was also interrupted because of accelerated cognitive deterioration in subjects receiving the drug. 5 Finally, two large studies of umibecestat (Generation 1 and 2), a BACE1 inhibitor, in cognitively normal subjects without evidence of A brain deposition but carrying the APOE4 allele, a genetic risk factor for AD, were also prematurely interrupted because of worsening cognitive function. 6 The failure of all these early intervention trials needs to be explained and has led to questioning of the amyloid hypothesis of AD, providing fresh impetus to the exploration of alternative etiologies and therapeutic strategies. One promising approach is therapeutic plasma exchange (TPE), which aims to supplement beneficial factors contained in young plasma that may promote neuronal survival and function and/or remove senescent detrimental factors that accumulate during aging.
PERIPHERAL INFLAMMATION IN ALZHEIMER'S DISEASE
The role of neuroinflammation in the pathogenesis of AD is gaining much interest as an avenue for new therapeutic approaches, particularly in view of the failure of most A -targeting drugs. Alteration of peripheral immune activity can affect the brain immune system 7 and be associated with increased risk of dementia. 8 A long-term longitudinal study of 1633 participants revealed a positive association between midlife peripheral inflammation and shrinkage of brain volume in late life. 9 A 6-month study in 300 community-dwelling subjects with mild to severe AD has shown that increases in serum tumor necrosis factor alpha (TNF-) levels were associated with increased rate of cognitive decline. 10 Circulating levels of peripheral cytokines have been shown to correlate to cytokine levels in the brain, AD severity, brain atrophy, 11 and cognitive performance. 12 High plasma levels of monocyte chemoattractant protein-1 (MCP-1) were found to be associated with AD severity and faster cognitive decline. 13 C-reactive protein, a biomarker of low-grade inflammation, was associated with shortened latency for AD onset in ApoE4 carriers. 14 Interestingly, longitudinal studies have found that associated peripheral inflammation may occur years before AD onset. 15 Longitudinal studies in cognitively healthy subjects have shown that high baseline plasma A 42 levels are associated with future increased risk of AD. 16 Low serum A -albumin complexes were associated with decreased levels of cerebrospinal fluid (CSF) A 42, increased levels of CSF phosphorylated-tau, and higher AD prevalence. 17 These observations suggested that a decreased ability of serum albumin to bind A in aging could slow the clearance of A from the central nervous system (CNS) and increase inflammatory response in the brain. Although elevated serum A levels and systemic inflammation markers are associated with neurodegeneration and AD onset, we do not know if there is a causal relationship and if lowering serum levels of A or inflammatory markers from the blood may be effective in AD patients.
REJUVENATION APPROACHES IN ANIMAL MODELS OF ALZHEIMER'S DISEASE
The hypothesis that removal of toxic and senescent factors from blood and simultaneously supplementing "rejuvenating" elements may be beneficial in aging and in AD has been quite extensively tested in animals ( Figure 1 ). Animal models of blood exchange used heterochronic parabiosis, a surgical procedure that joins the organs and circulatory systems of two animals of different ages. 18 Heterochronic parabiosis has been shown to stimulate neurogenesis and synaptic plasticity in the hippocampus 19 and improve cognitive function 20 of aged mice. These changes were correlated with increased cAMP response element-binding protein (CREB) signalling, which is implicated in synaptic plasticity. Moreover, exposure of young animals to aged blood has led to a significant reduction in neurogenesis in the dentate gyrus of the hippocampus, effects mediated by increased levels of C-C motif chemokine 11 (CCL-11). 20 Conversely, parabiosis between transgenic AD and wild-type mice determined deposition of A in vessel walls and parenchyma, and formation of AD-like protein aggregates in the brain of wild-type mice, showing that blood-derived A can enter the CNS determining degenerative changes. 21 Growth differentiation factor 11 (GDF-11) was found in higher concentrations in young mouse serum and was considered responsible for remodelling of cerebral vasculature and enhancing neurogenesis in aged mice. 22 In aged human APP transgenic mice, exposure to young blood through parabiosis or intravenous plasma administration significantly rescued neuronal synaptophysin and calbindin levels, and attenuated cognitive deficit while amyloid plaque deposition remained unaffected. 23 Abnormal phosphorylation of hippocampal extracellular signal regulated kinase (ERK), a kinase linked to AD and neurodegeneration, dropped to wild-type levels.
Peritoneal dialysis was found to decrease plasma A levels in chronic kidney disease patients. 24 This technique has been used as an alternative to parabiosis in APP/PS1 transgenic mice and significantly attenuated brain A burden, neuroinflammation, neurodegeneration, and cognitive deficits after a 1-month treatment. 24 Peritoneal dialysis might enhance A efflux from brain to blood, attenuating brain inflammation and improving A phagocytosis by microglia and clearance of hyperphosphorylated-tau.
Castellano et al. treated wild-type aged mice with human umbilical cord plasma proteins and found enhanced hippocampal activity and improved cognitive function in spatial learning, memory, and fearconditioning testing. 25 The tissue inhibitor of metalloproteinases 2 (TIMP2), a blood-borne factor, was found to be enriched in human cord plasma, young mouse plasma, and young mouse hippocampi. TIMP2 appeared in the brain after systemic administration and increased synaptic plasticity and hippocampus-dependent cognition. 25 Cognitive function (specifically hippocampal memory) was improved in aged mice by replacement of old peripheral hematopoietic cells with young ones, in association with reduced synapse loss and reduced activation of microglia. 26 While previous parabiosis studies have attributed cognitive aging, at least in part, to reduced neurogenesis, Das et al. reported that restoration of neurogenesis is not essential for the preservation of cognitive function. Microglial rejuvenation, via peripheral manipulation of the hematopoietic system, may be sufficient to maintain or restore hippocampal function. 26 In a recent in vitro study focusing on the identification of specific young blood factors able to enhance cognitive function, young mouse serum induced human cultured neurons, boosted synapse formation and connectivity, and enhanced NMDA synaptic responses. 27 Thrombospondin-4 (THBS4) and SPARC-like protein 1 (SPARCL1), two proteins enriched in young blood, where found to mediate these effects. Recombinant THBS4 and SPARCL1 were able to increase dendritic arborization, double synapse numbers, and increase synaptic NMDA receptors in cultured neurons. 27 Although these observations might not necessarily translate to humans, multiple preclinical studies are suggesting that TPE might work in both aging alone and AD.
It is still unclear how the plasma from young animals benefits the brain. Soluble factors in young plasma might interact with endothelial cells 22 targeting several anti-aging pathways and/or lowering A burden in the brain. A recent study found that intravenous injection of plasma collected from exercising (voluntarily running) mice into sedentary mice reduced baseline neuroinflammatory gene expression, suppressed lipopolysaccharide (LPS)-induced brain inflammation and improved contextual learning and memory. 28 These beneficial effects appeared mediated by a marked increase in complement cascade inhibitors including clusterin. 28 Although no age difference effect was explored in this study, its findings do add support to the principle of plasma-borne factors being able to affect cognition. Understanding which circulating plasma factors underlie the apparent restoration of age-related cognitive function loss might lead to the development of new molecular targets for intervention.
THERAPEUTIC PLASMA EXCHANGE IN THE CLINICAL PRACTICE
Therapeutic plasma exchange is used to remove patient plasma and replace it with albumin or other colloids, fresh frozen plasma, and/or crystalloids while maintaining normal plasma volume and osmotic balance. The purpose is the elimination of circulating toxic substances such as autoantibodies, alloantibodies, immune complexes, proteins, and toxins. 29 During plasma exchange, blood from the patient is passed through an apheresis device ("apheresis" is derived from a Greek word meaning "removal") which separates plasma from other blood components. This separation can be achieved either by centrifugal separation or by membrane filtration. Citrate anticoagulation is generally used with centrifugation devices, while heparin is used with F I G U R E 1 Overview of rejuvenating effects of blood exchange in preclinical studies. A, Young mouse blood factors thrombospondin-4 and SPARC-like protein 1 boosted neuronal function and N-methyl-D-aspartate synaptic responses of human cultured iPS-derived neurons, increasing dendrites and synapses formation. B, Young mouse blood enriched in growth differentiation factor 11 and tissue inhibitor of metalloproteinases 2 (TIMP2) enhanced cognitive function through cAMP response element-binding protein signalling in aged mice, improved vascular brain function, increased neurogenesis, and decreased AD-like pathology in transgenic animal models. Alzheimer's disease mice showed lowered brain abnormal phosphorylation of hippocampal extracellular signal regulated kinase, amyloid burden, and tau phosphorylation. Treatment with young hematopoietic cells or administration of human umbilical cord plasma enriched in TIMP2, decreased aging related circulating factors CCL-11, PLG, and improved cognition in old mice membrane filtration. The removed plasma has to be replaced, usually volume for volume, with an appropriate fluid that is able to preserve intravascular oncotic pressure, thus maintaining systemic blood pressure. A colloid solution (eg, albumin and/or plasma) or a combination of crystalloid/colloid solution can be used. Typically, 30 to 40 mL/kg of plasma (1 to 1.5 plasma volumes) are removed at each procedure and replaced with isotonic 4.5% or 5.0% human albumin solution.
Fresh frozen plasma is also used to replace clotting factors in patients at high risk of bleeding (such as those with Goodpasture syndrome and pulmonary hemorrhage) and is recommended in patients with thrombotic thrombocytopenic purpura. 30 Plasma exchange is widely used in the treatment of various pathologies, including Guillain-Barré syndrome, 31 multiple sclerosis, 32 inflammatory demyelinating polyradiculoneuropathy, 33 acute inflammatory demyelinating disease of the CNS, 34 and other peripheral neurological conditions. 35 The American Society for Apheresis (ASFA) produces regularly updated, evidence-based guidelines for TPE and Table 1 presents current first-line indications. 36 In addition to removing pathogenic substances, TPE may also remove normal plasma constituents, such as coagulation factors (which can cause transient changes in blood-clotting factor levels, and prothrombin and activated partial thromboplastin times), immunoglobulins, and platelets. However, in patients with normal bone marrow and liver function, endogenous synthesis replaces most coagulation factors and platelets within 2 to 4 days. 37 Therapeutic plasma exchange can be associated with a variety of risks; some such as nausea, vomiting, fainting, and hypotension could be symptoms of citrate toxic- 
PLASMA REPLACEMENT APPROACHES IN PATIENTS WITH ALZHEIMER'S DISEASE
The aging brain shows increased levels of many lysosomal proteins and inflammatory cytokines, while neurons and glial cells show dysfunctional endosomes, lysosomes, and autophagosomes. Whether these abnormalities contribute to aging or are just epiphenomena is unclear. Manipulation of autophagy-related genes in transgenic mice that overexpress APP or tau results in significant accumulation of these proteins or progression of AD. These observations indicate that aging and neurodegeneration are associated with a loss of proteostasis and it is likely that stabilization of protein homeostasis could benefit the aging brain. 38 The initial rationale for TPE in AD was that abnormal A accumulation in the brain is a pathological event in the AD process. There is a dynamic equilibrium between brain and plasma A levels and TPE could remove the excess of A from the brain and provide clinical benefits. Initial studies tried to verify whether TPE could modify the concentration of A in plasma and CSF; Table 2 summarizes the main clinical trials of different plasma replacement approaches in patients with AD.
Plasma exchange with 5% albumin
Grifols (Barcelona, Spain) is developing plasma exchange therapies with human plasma enriched with human albumin (Albutein R ) with or without human immunoglobulins (Flebogamma DIF R ). The rationale for using albumin-enriched plasma is that the vast majority of A circulating in blood (around 90%) is bound to albumin in a 1:1 ratio. 39 In vitro studies showed that human albumin produced by Grifols (Albutein R ) is able to bind A peptide. 40 Initial pilot studies of TPE in AD patients were carried out with 5% human albumin. In a 6-month, open label, uncontrolled pilot study, seven patients with mild-to-moderate AD underwent six plasma exchange infusions over 3 weeks. 41 A 21-week, double-blind, controlled study (NCT00742417) evaluated the safety, tolerability, and preliminary efficacy of TPE with 5% albumin in 42 mild-to-moderate AD patients. 42 Patients on TPE received two infusions/week for 3 weeks followed by one infusion/week for 6 weeks and, finally, one infusion every 2 weeks for an additional 12 weeks. The control group received sham infusions.
Patients were followed up for 24 weeks after the treatment period.
One patient in the control group and two patients in the TPE groups did not complete the full 21-week treatment part of the study. Daily Living (ADCS-ADL) (P = .050). A possible explanation for these findings is that TPE had a negative impact on activities of daily living during the intensive treatment phases, while psychiatric symptoms may have been impacted by the patients having to tolerate a catheter inserted in their chests, and the discomfort caused by treatmentrelated metabolic alterations. However, an increase in psychiatric symptoms has also been observed with other anti-A drugs, especially -secretase and -secretase inhibitors, and has been linked to reductions of brain A levels. 43 Conversely, infusions of young fresh frozen plasma in AD patients have been associated with improved activities of daily living and functionality. 44 A 14-month, double-blind, placebo-controlled study (Alzheimer's Management By Albumin Replacement, AMBAR, NCT01561053) evaluated the effects of different plasma replacement levels of albumin (5% and 20%), with or without intravenous immunoglobulin (5%) in 347 mild-to-moderate AD patients. 45 The study was conducted at 41 sites started treatment and 72% of them completed the study ( Table 3 ).
The number of patients who did not complete the study were similar in control and low-albumin groups (20.0% and 21.8%, respectively) but were higher in the TPE groups that included immunoglobulins (34.9% and 34.6%, respectively; Table 3 ). Similarly, the number of patients with serious adverse events were similar in control and in low albumin-groups (10.1% and 10.3%, respectively), but were two numbers higher in the groups that received immunoglobulins (22.1% and 20.3%, respectively; Table 3 ). There were two deaths during the study, both in the low-albumin+low-immunoglobulin group (one suicide, other cause unstated). The most frequent complications in the TPE groups compared to controls were hypotension (21.8% vs 1.3%, respectively) and muscle pain (21.4% vs 6.3%). Regarding efficacy, while each of the three treatment groups showed arithmetically less decline on the ADAS-Cog than the control group, the differences (1.7 to 2.1 points) were not statistically significant (Table 3 ). However, when the three treatment arms were combined the 66% lesser decline in the ADAS-Cog compared to placebo approached statistical significance (P = .06). On the ADCS-ADL, the treated groups performed insignificantly better than the control groups (2.8 to 4.7 points) but the pooled group declined 52% less than those on placebo (P = .03). A in the TPE groups the decline was less on both measures (Table 3) .
When the three treatment groups were combined (n = 83) the mean decline on both ADAS-Cog (2.6 ± 1.1 points, P = .05) and ADCS-ADL (−5.5 ± 1.3 points, P = .002) was significantly less compared to the control group (Figure 2) . At the AAIC 2019 conference, it was reported that the Clinical Dementia Rating-Sum of Boxes (CDR-SB) and the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) scales declined significantly less rapidly in the pooled TPE groups than in placebo-treated patients. 47 In both conventional and low-volume plasmapheresis groups, a saw-tooth profile was observed for plasma A levels. 47 
Plasma infusion with young plasma

Plasma infusion with plasma fractions
The rationale for using a plasma protein fraction is based on several factors. Although plasma is widely used, there are risks such as the potential transfer of pathogens, histo-incompatibility, and allergic reactions to proteins such as clotting factors and immunoglobulins. Safer products have been developed by pooling plasma from multiple donations, fractionating the plasma into more defined products, and including additional processing steps to minimize the potential for pathogen transmission. The investigation of plasma fractions in AD is also supported by the theory that there are specific components of plasma that actually drive beneficial functions in aging.
GRF6019 is a human plasma protein fraction depleted of coagulation factors and gamma globulins and containing about 400 proteins believed essential to the beneficial effects of whole plasma. GRF6019 is being developed by Alkahest (San Carlos, California) in collaboration with Grifols (Barcelona, Spain). No data on GRF6019 have been fully published and all the information available is from conferences or company press releases. In animal models of human aging, GRF6019
was claimed to enhance neurogenesis, improve age-related deficits in learning and memory, and reduce neuroinflammation. 48 Studies performed in aged mice at Alkahest compared intermittent dosing with plasma fractions (two to three times per week for up to 12 weeks) with pulsed dosing (daily infusion for 5 to 7 consecutive days). Pulsed dosing was found to be superior to intermittent dosing on behavioral and neurogenesis endpoints. Benefits after pulse dosing lasted up to 3 months, demonstrating that continuous dosing was not required in mice. 48 A 24-week, dose-range finding study (NCT03520998) evaluated the safety and tolerability of two intravenous dose regimens of GRF6019 (100 or 250 mL each day for 5 consecutive days administered at Week 1 and at Week 13) in 52 subjects with mild-to-moderate AD. 49 
CLINICAL PERSPECTIVES
Plasma replacement studies in transgenic mouse models of AD suggest that factors present in the circulatory system can either worsen or attenuate brain pathological hallmarks and cognitive performance. 38 However, observations in mouse models of AD do not necessarily translate to humans, particularly because the models used miss some critical aspects of the disease (such as neurofibrillary tangle formation and neuronal death), and there has been no systematic work to optimize the experimental conditions of TPE (duration of heterochronic parabiosis, frequency, duration, and volume of plasma administration).
Nevertheless, these studies are important because they provide the first demonstration that plasma exchange has potential therapeutic effects.
Initial clinical results obtained with TPE in AD patients are encouraging but we must point out that there are several methodological limitations that could undermine the results and their applicability to larger AD groups. Limited sample size of the available studies may have impacted the homogeneity of treatment groups at baseline, favoring (by chance) specific treatment arms. This is true also for the AMBAR study that randomized a more consistent group of patients (n = 347) but adopted a complicated study design involving four treatment F I G U R E 3 Benefits of young plasma: working hypothesis. A, Amyloid plaques and tau tangles in the Alzheimer's disease (AD) brain induce neuronal synapse loss and apoptosis. Activated microglia responsible for the clearance of cellular debris activate the innate and adaptive immune systems releasing inflammatory cytokines. Protracted glial-mediated inflammation damages brain endothelial cells, exposing damage-associated molecular pattern signals that overstimulate the peripheral immune response, activating complement and inducing a persistent inflammatory state, as well as decreasing amyloid (A ) clearance by dysfunctional albumin. These effects contribute to cognitive deficits and neuronal death. B, Replacement of old plasma with young plasma exposes the AD-damaged brain endothelium to protective factors like SPARC-like protein 1, tissue inhibitor of metalloproteinases 2, and thrombospondin-4, that might lead to beneficial effects such as increased neurogenesis, angiogenesis, and activation of antiapoptotic pathways. Young hematopoietic cells may decrease circulating proinflammatory molecules, induce anti-inflammatory cytokines, and increase functional albumin (thus increasing A clearance). Reduced A and attenuated central and peripheral inflammation might improve cognition, enhance hippocampal function, and increase neuronal survival groups and two study phases. In addition, AD patients enrolled in TPE studies may not be representative of general AD population because of several adopted exclusion criteria (such as abnormal coagulation parameters, hypohemoglobinemia, bradycardia, increased risk of allergic reactions). Most importantly, it should be noted that these initial studies, including the AMBAR trial, did not require biomarker-proven brain A deposition (either by A -PET or CSF A 42 levels) at entry. In the AMBAR study, 28% of screened patients did not show evidence of A brain deposition, meaning that these patients had an underly- Although TPE is safely used in some neurologic diseases, 50 clinical complications are described and should be expected. 51 Therapeutic plasma exchange in AD patients has to be considered with additional caution because the elderly subjects involved will be particularly sensitive to complications. Common risks include acute lung injury, circulatory overload, and allergic and/or anaphylactic reactions. Less common risks include transmission of infections, febrile nonhemolytic transfusion reactions, red blood cell alloimmunization, and hemolytic transfusion reactions. 50 Although the majority of these adverse effects are not lethal and are adequately managed in clinical practice, if TPE can be effective in AD patients it will be important to identify the key factors responsible, as they might lead to the development of molecule interventions with a better efficacy/risk profile.
CONCLUSIONS
Initial clinical studies with TPE using young plasma or young plasma enriched with albumin and/or immunoglobulin or selected plasma fractions have raised hopes for the management of both mild-to-moderate and severe AD patients. This is because clinical studies with TPE have been conducted in patients with established AD, a group of patients that has during the last 5 to 10 years been excluded from experimental trials with potential disease-modifying drugs while the candidates that had already failed in established disease were tested in subjects with prodromal AD or even cognitively normal subjects at risk of developing AD. Thus, effective therapies in patients with frank AD are much needed. While initial results are encouraging, they are from small pilot studies that suffer methodological limitations such as a lack of real control groups and double-blind conditions. In addition, the higher frequency of drop-out in patients undergoing TPE compared to controls, may have led to overestimation of the beneficial effects; it is well known that in controlled AD trials discontinuing patients are generally those with the worst cognitive and functional performance and concomitant morbidity. Larger, longer, and fully blinded studies in AD patients with biomarker-confirmed brain A pathology are needed in the future to confirm the real clinical potential of TPE in AD. The issues of potential adverse effects and medical feasibility of chronic TPE in the particularly sensitive patient population represented by elderly people with established dementia need to be carefully considered.
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